Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years.~* Recipients of donated oocytes.~* Pregnant women.~* Single or twin gestations.~* Patients who accept the conditions of the study by signing the appropriate informed consent.~Exclusion Criteria:~* Known allergy to acetylsalicylic acid .~* Personal history of peptic ulcer.~* Triplets.~* Use of prostaglandin inhibitors within 10 days prior to baseline.~* Personal history of chronic kidney, thyroid, liver or heart disease.~* Psychiatric or cognitive pathology that prevents understanding of the conditions of informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- acetylsalicylic acid (Type: EXPERIMENTAL): This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36

Based on this trial design, predict the completion outcome and termination type (if applicable).